Guillain-Barré Syndrome

Area of Science:

• Neurology
• Immunology
• Pathogenesis of Neuropathic Illnesses

Background:

• Guillain-Barré syndrome (GBS) is a significant cause of acute flaccid paralysis globally.
• Current treatments like plasma exchange and IV immunoglobulin (IVIg) are insufficient for a notable patient subset.
• Recent research has elucidated the role of innate immune effectors in GBS pathogenesis.

Purpose of the Study:

• To review the clinical aspects, diagnosis, prognosis, pathogenesis, and treatments for Guillain-Barré syndrome (GBS).
• To highlight the unmet need for novel GBS therapies due to limited efficacy of existing treatments.
• To discuss emerging prognostic models and novel therapeutic agents in clinical development.

Main Methods:

• Review of clinical features, diagnostic criteria, and differential diagnoses of GBS.
• Analysis of prognostic models for predicting functional recovery and ventilation needs.
• Examination of recent findings on GBS pathogenesis, focusing on innate immunity.
• Assessment of current and investigational treatments, including complement inhibitors.

Main Results:

• Prognostic models for GBS outcomes are now available and clinically applicable.
• Innate immune components, including complement and macrophages, are key mediators of nerve damage in GBS.
• Two complement inhibitors are in clinical trials for GBS treatment efficacy.

Conclusions:

• GBS remains a critical neurological disorder with a need for improved therapeutic options.
• Advances in understanding GBS pathogenesis are paving the way for targeted therapies.
• New treatments, particularly complement inhibitors, show promise for GBS management.